Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00543920
First received: October 5, 2007
Last updated: November 6, 2014
Last verified: November 2014

October 5, 2007
November 6, 2014
August 2002
February 2003   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00543920 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
Not Provided

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Anxiety Disorders
Drug: MK0777
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
February 2003
February 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of General Anxiety Order

Exclusion Criteria:

  • Women who are pregnant or breast-feeding
  • History of severe drug reaction
  • History of severe drug withdrawal symptoms such as seizures or delirium
  • Disease of cardiovascular system
  • Disease of the liver, kidneys, endocrine system, metabolic system or eyes
  • History of seizures or seizure disorder
  • History of drug or alcohol abuse
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00543920
0777-020, 2007_633
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP